Vicks Nears $1 Bil. In Sales Under “Focused” Growth Strategy – P&G
This article was originally published in The Tan Sheet
The Vicks brand of over-the-counter cough, cold and flu products is "on its way" to becoming a $1 billion franchise, according to Procter & Gamble President and CEO A.G. Lafley
You may also be interested in...
Procter & Gamble's Prilosec OTC (omeprazole) reached nearly 40 percent market share in the firm's latest quarter to lead the OTC heartburn medication segment
GSK partners with biotech firm Mammoth Biosciences to develop a home-use OTC nasal swab test for COVID-19 that works in less than 20 minutes. Mammoth says the firms will seek an FDA emergency use authorization for the test, roll it out first to clinics and will seek approval for OTC sales.
Thync Global’s Zing Energy neurostimulation patch and Tesla Nootropics’ Nubrain Brainstorm caffeine-free water are promoted as alternatives to caffeine and energy drinks. They join a market dominated by big brands but with competition growing from products that boost energy without caffeine and sugar.